Gut microbiome is not associated with mild cognitive impairment in Parkinson's diseaseOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers compared gut microbial features across three groups from the Luxembourg Parkinson's Study: people with Parkinson's disease (PD) and mild cognitive impairment (PD-MCI, n=58), PD without cognitive impairment (PD-NC, n=60), and cognitively normal controls (n=90). The aim was to see whether a prior report of a distinct MCI-related microbiome signature would replicate in a larger, separate cohort.
How was it studied?
Stool samples were profiled by 16S rRNA gene sequencing (V3-V4 regions) after strict diagnostic and data-quality exclusions, leaving 208 individuals for analysis. The team compared alpha diversity, beta diversity, and differential taxon abundance using three separate statistical tools (DESeq2, ANCOM-BC2, and DA.lic), adjusting for age, sex, BMI, antibiotic use, constipation, and education.
What did they find?
PD groups overall differed from controls in community composition and in several taxa, consistent with prior PD microbiome literature. However, within PD, beta diversity did not differ between PD-MCI and PD-NC, and only one of three statistical tests found any taxa distinguishing the two groups, with no overlap with taxa reported in the earlier MCI study.
Why it matters
The findings did not support a reproducible, MCI-specific gut microbiome signature in Parkinson's disease, contradicting an earlier single-cohort report. This suggests claims of a distinct PD-MCI microbiome need replication in additional independent cohorts before being treated as established.